CareFusion

CareFusion
Share

CareFusion

 •  February 13

The BD Onclarity™ HPV Assay can detect 14 high-risk HPV types and provide additional information to guide physician decision-making FRANKLIN LAKES, N.J., February 13, 2018 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pre-market approval from the U.S. Food and...

CareFusion

 •  January 15

New Test Provides Diagnostic Results Up to 10 Times Faster Than Traditional Tests FRANKLIN LAKES, N.J., and WAGENINGEN, The Netherlands, January 15, 2018 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a...

CareFusion

 •  December 4, 2017

Experience the Advantage of Complete Medication Management at #ASHP17 BD Booth 721 ORLANDO, Dec. 4, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today revealed several technology innovations to further optimize the entire medication management process at this year's American Society of...

CareFusion

 •  November 16, 2017

FRANKLIN LAKES, N.J., Nov. 16, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and...

CareFusion

 •  September 26, 2017

Fully-automated BD Phoenix™ CPO detect test helps detect dangerous pathogens FRANKLIN LAKES, N.J., September 26, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO)....

CareFusion

 •  September 19, 2017

FRANLIN LAKES, N.J., Sept. 19, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the BD Ultra-Fine™ micro pen needle 6mm x 32G for use with leading pen injection devices, that is set for distribution starting September 2017. With this launch, BD is providing...

CareFusion

 •  June 6, 2017

Extends BD MAX™ Enteric Panel Portfolio with latest Molecular Test that Targets Infectious Diarrhea
FRANKLIN LAKES, N.J., June 5, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its newly developed molecular test for detecting harmful intestinal bacteria causing infectious...

CareFusion

 •  April 27, 2017

Mass spectrometry identification solution may help hospitals manage antimicrobial resistance more effectively
FRANKLIN LAKES, N.J., Apr. 27, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global distribution of a complete portfolio of products for mass spectrometry that...

CareFusion

 •  April 24, 2017

FRANKLIN LAKES, NJ and MURRAY HILL, NJ (April 23, 2017) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD...

CareFusion

 •  April 4, 2017

Expands Infusion Portfolio for Ambulatory, Home Care and Specialty Applications
FRANKLIN LAKES, N.J., April 4, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems...